US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while viewing subcutaneous PD-1s as a practical evolution in care delivery more ...
Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback